Search Result

Results for "

novo

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (5) Akt (1) AMPK (2) Amylin Receptor (1) Amyloid-β (1) Antibiotic (2) Antifolate (6) Apoptosis (20) Arenavirus (1) ATP Synthase (3) Autophagy (8) Bacterial (4) Bcl-2 Family (12) Carbonic Anhydrase (3) Carnitine Palmitoyltransferase (CPT) (1) Caspase (5) Ceramidase (1) Claudin (1) Cytochrome P450 (2) DAGL (1) Dihydroorotate Dehydrogenase (3) DNA Methyltransferase (5) DNA-PK (1) DNA/RNA Synthesis (27) Drug Derivative (1) Drug Intermediate (4) Drug Metabolite (1) Emopamil Binding Protein (1) Endogenous Metabolite (33) FABP (1) Fatty Acid Synthase (FASN) (5) Fungal (1) GLP Receptor (8) GLUT (2) Glycosyltransferase (1) HBV (2) HCV (7) Histone Methyltransferase (1) HIV (5) IFNAR (1) Influenza Virus (1) Insulin Receptor (8) Interleukin Related (5) Isotope-Labeled Compounds (16) JAK (2) Keap1-Nrf2 (1) Lipase (1) Mitochondrial Metabolism (2) MMP (1) mTOR (1) NF-κB (1) NO Synthase (2) Nucleoside Antimetabolite/Analog (11) p38 MAPK (8) PGC-1α (1) Phosphoglycerate Dehydrogenase (PHGDH) (3) PI3K (1) PKC (2) Potassium Channel (1) PPAR (4) Reactive Oxygen Species (ROS) (2) Reference Standards (8) Reverse Transcriptase (3) SARS-CoV (1) SHMT (1) SOD (1) Tau Protein (1) Thymidylate Synthase (1) VD/VDR (1) α-synuclein (9)
By Research Areas:	Cancer (48) Cardiovascular Disease (4) Endocrinology (3) Infection (27) Inflammation/Immunology (14) Metabolic Disease (41) Neurological Disease (12)
Oligonucleotides:	Guanosine (1) Nucleotide Analogs (3) Nucleoside Analogs (1) Cytidine Nucleotide (2)

121

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N6798

Myriocin 10+ Cited Publications Thermozymocidin; ISP-I	HCV Antibiotic	Infection
Myriocin (Thermozymocidin), a fungal metabolite could be isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids. Myriocin suppresses replication of both the subgenomic HCV-1b replicon and the JFH-1 strain of genotype 2a infectious HCV, with an IC₅₀ of 3.5 μg/mL for inhibiting HCV infection .

HY-N2327

Oleamide 1 Publications Verification	Endogenous Metabolite	Others
Oleamide is an endogenous fatty acid amide which can be synthesized de novo in the mammalian nervous system, and has been detected in human plasma.

HY-N6719

Fumonisin B1 5+ Cited Publications	Acyltransferase	Infection
Fumonisin B1 is a mycotoxin produced from Fusarium moniliforme. Fumonisin B1 is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis. Fumonisin B1 is the most abundant and toxic fumonisin .

HY-B0199

Mycophenolate Mofetil Maximum Cited Publications 12 Publications Verification RS 61443; TM-MMF	Drug Metabolite Apoptosis Endogenous Metabolite Bacterial	Cancer
Mycophenolate mofetil (RS 61443) is the morpholinoethylester proagent of Mycophenolic acid. Mycophenolate mofetil inhibits de novo purine synthesis via the inhibition of inosine monophosphate dehydrogenase (IMPDH). Mycophenolate mofetil shows selective lymphocyte antiproliferative effects involve both T and B cells, preventing antibody formation .

HY-116705

2-Deoxy-2-fluoro-L-fucose 1 Publications Verification	Glycosyltransferase	Cancer
2-Deoxy-2-fluoro-L-fucose, an L-fucose analog, is a fucosylation inhibitor. 2-Deoxy-2-fluoro-L-fucose inhibits de novo synthesis of GDP-fucose in mammalian cells. Fucosylation is a relatively well-defined biomarker for progression in many human cancers; for example, pancreatic and hepatocellular carcinoma .

HY-125818

Cytidine-5'-triphosphate 3 Publications Verification Cytidine triphosphate; 5'-CTP	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Endogenous Metabolite	Metabolic Disease
Cytidine 5′-triphosphate (Cytidine triphosphate; 5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule in the de novo pyrimidine biosynthetic pathway in T. gondii .

HY-13560

AVN-944 5 Publications Verification VX-944	Arenavirus DNA/RNA Synthesis Apoptosis Caspase Bcl-2 Family	Infection Cancer
AVN-944 (VX-944) is an orally active, potent, selective, noncompetitive and specific inhibitor of IMPDH (inosine monophosphate dehydrogenase). AVN-944 is an essential rate-limiting enzyme in de novo guanine nucleotide synthesis. AVN-944 is also an inhibitor of arenavirus RNA synthesis, and blocks arenavirus infection. AVN-944 has broad anti-cancer activities, and can be used for multiple myeloma (MM) and acute myeloid leukemia (AML) research .

HY-14521

Lometrexol 3 Publications Verification DDATHF	Antifolate Apoptosis Caspase Bcl-2 Family	Cancer
Lometrexol (DDATHF), an antipurine antifolate, can inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT) but do not induce detectable levels of DNA strand breaks. Lometrexol can further inhibit de novo purine synthesis, causing abnormal cell proliferation and apoptosis, even cell cycle arrest. Lometrexol has anticancer activity. Lometrexol also is a potent human Serine hydroxymethyltransferase1/2 (hSHMT1/2) inhibitor .

HY-126585

SAICAR 4 Publications Verification	Endogenous Metabolite	Cancer
SAICAR is an intermediate of de novo purine nucleotide biosynthesis, activates pyruvate kinase isoform M2 (PKM2) in an isozyme-selective manner, with an EC₅₀ of 0.3 mM. SAICAR stimulates PKM2 and promotes cancer cell survival in glucose-limited conditions .

HY-18762

6-Thio-2'-Deoxyguanosine 2 Publications Verification 6-thio-dG; β-TGdR	DNA/RNA Synthesis	Cancer
6-Thio-2'-Deoxyguanosine is a nucleoside analogue that can be incorporated into de novo-synthesized telomeres by telomerase.

HY-122122

ML-60218 5+ Cited Publications	DNA/RNA Synthesis	Infection Cancer
ML-60218 is a broad-spectrum RNA pol III inhibitor, with IC₅₀s of 32 and 27 μM for Saccharomyces cerevisiae and human. ML-60218 disrupts already assembled viroplasms and to hamper the formation of new ones without the need for de novo transcription of cellular RNAs .

HY-109168

Bersacapavir 2 Publications Verification JNJ-6379; JNJ-56136379	HBV DNA/RNA Synthesis	Infection
Bersacapavir (JNJ-6379) is an HBV capsid assembly modulator. Bersacapavir exerts a dual mechanism of action against both early and late stages of HBV infection by forming complete genome-free empty capsids and inhibiting de novo synthesis of cccDNA. Bersacapavir inhibits HBV replication. Bersacapavir can be used in the research of hepatitis B .

HY-112732B

Sparfosic acid trisodium 4 Publications Verification	Apoptosis	Metabolic Disease Cancer
Sparfosic acid trisodium is a DNA antimetabolite agent and a potent inhibitor of aspartate transcarbamoyl transferase. Aspartate transcarbamoyl transferase catalyzes the second step of de novo pyrimidine biosynthesis. Sparfosic acid trisodium synergistically enhances the cytotoxicity of a combination of 5-fluorouracil (5-FU) and interferon-alpha (IFN) against human colon cancer cell lines .

HY-P2048

MOTS-c (human) 1 Publications Verification	Apoptosis GLUT AMPK	Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
MOTS-c (human) is a blood-brain barrier-penetrating, mitochondrial-derived peptide that modulates the AMPK/PGC-1α pathway to enhance insulin sensitivity. MOTS-c (human) inhibits the folate cycle and de novo purine synthesis, increases AICAR levels to activate AMPK, and then regulates the Nrf2/Keap1 antioxidant pathway and inhibits the NF-κB inflammatory pathway, while promoting mitochondrial biogenesis and energy metabolism. MOTS-c (human) has the effects of improving glucose and lipid metabolism, anti-oxidative stress, anti-inflammatory and neuroprotection, and can be used in the study of type 2 diabetes, traumatic brain injury, inflammatory diseases and aging-related metabolic disorders .

HY-112732

Sparfosic acid 4 Publications Verification	Apoptosis	Metabolic Disease Cancer
Sparfosic acid, a DNA antimetabolite agent, is a potent inhibitor of aspartate transcarbamoyl transferase, the enzyme catalyzing the second step of de novo pyrimidine biosynthesis. Sparfosic acid synergistically enhances the cytotoxicity of a combination of 5-fluorouracil (5-FU) and interferon-alpha (IFN) against human colon cancer cell lines .

HY-100012

CBR-5884 15+ Cited Publications	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
CBR-5884 is an active, selective inhibitor of phosphoglycerate dehydrogenase (PHGDH) with an IC₅₀ of 33 μM. CBR-5884 inhibits de novo serine synthesis in cancer cells and is selectively toxic to cancer cell lines with high serine biosynthetic activity. CBR-5884 selectively inhibits the proliferation of melanoma and breast cancer lines that have a high propensity for serine synthesis .

HY-158712

3'-ONH2-dATP sodium solution (100 mM)		Others
3'-ONH2-dATP (sodium) solution (100 mM) is a 3'-O-blocked reversible terminator deoxynucleotide triphosphate.3'-ONH2-dATP (sodium) solution (100 mM) stops DNA polymerization after single-nucleotide addition to an initiator strand, and its 3'-ONH2 blocking group can be removed to restore a free 3'-OH for subsequent extension.3'-ONH2-dATP (sodium) solution (100 mM) incorporates into an oligonucleotide chain by engineered terminal deoxynucleotidyl transferase from Zonotrichia albicollis to enable template-free, stepwise de novo enzymatic DNA synthesis .

HY-100954

2,4-Diamino-6-hydroxypyrimidine 5+ Cited Publications	NO Synthase	Inflammation/Immunology
2,4-Diamino-6-hydroxypyrimidine is a specific GTP cyclohydrolase I inhibitor (the rate-limiting enzyme in de novo pterin synthesis). 2,4-Diamino-6-hydroxypyrimidine blocks Tetrahydrobiopterin (BH4) synthesis and suppresses NO production .

HY-N6614

L-Galactose	VD/VDR	Others
L-Galactose is a key intermediate in the de novo synthesis of vitamin C (L-ascorbic acid) in plants. It is converted into L-ascorbic acid by participating in the VTC2 cycle and enzymatic steps, exerting antioxidant activities, maintaining cell structure, and participating in the carbon flow distribution of photosynthesis. L-Galactose can be used to study the analysis of the synthesis pathway of vitamin C in plant physiology .

HY-19939S

VX-984 4 Publications Verification M9831	DNA-PK	Cancer
VX-984 is an orally active, potent, selective and BBB-penetrated DNA-PK inhibitor. VX-984 efficiently inhibits NHEJ (non-homologous end joining) and increases DSBs (DNA double-strand breaks). VX-984 can be used for glioblastomas (GBM) and non-small cell lung cancer (NSCLC) research. VX-984 is a de novo deuterium .

HY-131968

BMS-986202 1 Publications Verification	JAK Cytochrome P450	Inflammation/Immunology
BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

HY-177105

JNJ-6640	Bacterial	Infection
JNJ-6640 is an inhibitor targeting mycobacterial PurF (the first enzyme in the de novo purine biosynthesis pathway) with potent anti-tuberculosis activity. JNJ-6640 exhibits bactericidal activity against Mycobacterium tuberculosis in vitro, with an MIC₉₀ of 8.6 nM. JNJ-6640 disrupts de novo purine biosynthesis, inhibits M. tuberculosis DNA replication in vivo. JNJ-6640 exhibits anti-tuberculosis efficacy in acutely infected mice. JNJ-6640 can be used for the study of tuberculosis .

HY-123269

PKUMDL-WQ-2101	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
PKUMDL-WQ-2101 is a non-NAD ⁺-competing allosteric phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC₅₀ of 34.8 μM. PKUMDL-WQ-2101 exhibits antitumor activity .

HY-123418

PKUMDL-WQ-2201	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
PKUMDL-WQ-2201 is a PHGDH non-NAD+-competing allosteric inhibitor (IC₅₀=35.7 μM). PKUMDL-WQ-2201 also inhibits PHGDH mutants with IC₅₀s of 69 μM (T59A) and >300 μM (T56AK57A), respectively. PKUMDL-WQ-2201 inhibits de novo serine synthesis in cancer cells, and reduces tumor growth .

HY-117771

DO34 5 Publications Verification	DAGL	Neurological Disease Metabolic Disease
DO34 is a selective DAGL inhibitor, with an IC₅₀ of 6 nM for DAGLα conversion of SAG to 2-AG. DO34 blocks de novo 2-AG synthesis, and suppresses tonic CB₁ receptor activation. DO34 blocks depolarization-induced suppression of excitation and inhibition in the cerebellum and hippocampus. DO34 regulates feeding behavior and locomotor activity in mice. DO34 abolishes AM251-mediated enhancement of parallel fiber-evoked excitatory postsynaptic currents in cerebellar slices from MAGL global knockout mice. DO34 can be used for the research of energy balance disorder and neuroinflammation .

HY-W506116

Ostruthin Ostruthine	Bacterial DNA/RNA Synthesis	Cardiovascular Disease Infection
Ostruthin is a natural coumarin compound with bacterial and antimycobacterial activities . Ostruthin inhibits the growth of mycobacteria and Staphylococcus aureus. Ostruthin suppresses vascular smooth muscle cell proliferation as well as de novo cellular DNA synthesis. Ostruthin is applicable to research related to mycobacterial infections and cardiovascular and cerebrovascular diseases .

HY-109195

Vebicorvir 2 Publications Verification ABI-H0731	HBV	Infection Inflammation/Immunology
Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor. Vebicorvir (ABI-H0731) suppresses covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC₅₀s from 1.84 μM to 7.3 μM .

HY-W013100

Cytidine-5'-triphosphate disodium 3 Publications Verification Cytidine triphosphate disodium; 5'-CTP disodium	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Endogenous Metabolite	Metabolic Disease
Cytidine-5'-triphosphate (Cytidine triphosphate; 5'-CTP) disodium is a nucleoside triphosphate, that is invovled in biosynthesis of DNA, RNA and lipid. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate disodium is an essential biomolecule in the de novo pyrimidine biosynthetic pathway in T. gondii .

HY-144433

DNMT3A-IN-1 2 Publications Verification	DNA Methyltransferase	Infection
DNMT3A-IN-1 (compound 1) is an effective and selective DNMT3A inhibitor. DNMT3A-IN-1 exhibits inhibitory activity against DNMT3A, with K_I values ranging from 9.16 to 18.85 μM (AdoMet) and 11.37 to 23.34 μM (poly dI-dC). DNMT3A-IN-1 can induce apoptosis in acute myeloid leukemia (AML) cell lines (Apoptosis) .

HY-N6723

Fumonisin B2	Ceramidase Acyltransferase	Infection Cancer
Fumonisin B2 is a selective ceramide synthase inhibitor and carcinogenic mycotoxin with toxicity comparable to that of Fumonisin B1 (HY-N6719). Fumonisin B2 inhibits de novo sphingolipid biosynthesis by blocking the amide bond formation between fatty acids and dihydrosphingosine, which leads to a massive intracellular accumulation of free dihydrosphingosine, altered sphingosine levels, subsequent inhibition of cell proliferation, and induction of cell death. Fumonisin B2 is used to investigate the pathogenesis of diseases associated with Fusarium verticillioides contamination, including equine leukoencephalomalacia, porcine pulmonary edema syndrome, human esophageal cancer, and rat hepatocellular carcinoma .

HY-156259

PF-07202954	Acyltransferase	Inflammation/Immunology
PF-07202954 is an orally active, highly selective DGAT2 inhibitor with an IC₅₀ of 10 nM against human DGAT2 and an IC₅₀ of 17 nM against rat DGAT2. PF-07202954 reduces triglyceride synthesis, decreases hepatic triglyceride content and plasma triglyceride levels, inhibits de novo lipogenesis, and suppresses the hepatic SREBP signaling pathway as well as the expression of SREBP target genes. PF-07202954 is applicable to research related to non-alcoholic steatohepatitis .

HY-75800

Lomibuvir 2 Publications Verification VX-222	DNA/RNA Synthesis HCV	Infection
Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a K_d of 17 nM. Lomibuvir inhibits the 1b/Con1 HCV subgenomic replicon with an EC₅₀ of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis .

HY-150252A

ATIC-IN-1 acetate 1 Publications Verification	Endogenous Metabolite	Cancer
ATIC-IN-1 (compound 14) acetate is an inhibitor targeting to Aminoimidazole carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase (ATIC) dimerization with a K_i value of 685 nM, whcich catalyzes de novo purine biosynthesis. ATIC dimerization is crucial for its aminoimidazole carboxamide ribonucleotide (AICAR) transformylase activity. ATIC-IN-1 acetate exhibits anti-tumor activity via reduction in cell numbers and cell division rates .

HY-N8060A

Orotidine 5′-monophosphate trisodium 1 Publications Verification Orotidine monophosphate trisodium; Orotidylic acid trisodium	Endogenous Metabolite DNA/RNA Synthesis	Metabolic Disease
Orotidine 5'-monophosphate trisodium is a pyrimidine nucleotide. Orotidine 5'-monophosphate trisodium is synthesized via the de novo synthesis pathway for DNA synthesis in a large number of microorganisms including M. tuberculosis, S. cerevisiae, S. typhimurium and P. falciparum to name a few. The synthesis of orotidine 5'-monophosphate trisodium uses phosphoribosyl pyrophosphate (PRPP) and orotic acid (OA) as the substrates catalyzed by orotate phosphoribosyltransferase (OPRT) .

HY-43515

ESI1	Endogenous Metabolite	Metabolic Disease
ESI1 is a small molecule epigenetic silencing inhibitor. ESI1 can trigger the formation of nuclear condensates of key lipid metabolism regulators SREBP1/2, concentrating transcriptional co-activators to drive lipid/cholesterol biosynthesis. ESI1 can promote myelin regeneration in demyelinated animal models and facilitate de novo myelination on regenerating CNS axons, reversing age-related declines in cognitive abilities .

HY-P2048A

MOTS-c(human) acetate 1 Publications Verification	AMPK GLUT	Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
MOTS-c (human) acetate is a blood-brain barrier-penetrating, mitochondrial-derived peptide that modulates the AMPK/PGC-1α pathway to enhance insulin sensitivity. MOTS-c (human) acetate inhibits the folate cycle and de novo purine synthesis, increases AICAR levels to activate AMPK, and then regulates the Nrf2/Keap1 antioxidant pathway and inhibits the NF-κB inflammatory pathway, while promoting mitochondrial biogenesis and energy metabolism. MOTS-c (human) acetate has the effects of improving glucose and lipid metabolism, anti-oxidative stress, anti-inflammatory and neuroprotection, and can be used in the study of type 2 diabetes, traumatic brain injury, inflammatory diseases and aging-related metabolic disorders .

HY-133154

Carboxyaminoimidazole ribotide 2 Publications Verification CAIR; 4-Carboxy-AIR	Endogenous Metabolite	Infection
Carboxyaminoimidazole ribotide (CAIR) is a metabolite of E. coli. Carboxyaminoimidazole ribotide can be used to detect distinctive features of E. coli PurE active site and synthesis fungal de novo purine .

HY-133157

FAICAR 5-Formamidoimidazole-4-carboxamide ribotide	DNA/RNA Synthesis	Infection
FAICAR (5-Formamidoimidazole-4-carboxamide ribotide) is a purine nucleotide and the IMP cyclohydrolase substrate of Cryptococcus neoformans ATIC. It is a key intermediate in the de novo purine synthesis pathway. FAICAR can be used in studies related to Cryptococcus neoformans infection .

HY-133033

COQ7-IN-1	Mitochondrial Metabolism	Metabolic Disease
COQ7-IN-1, a highly potent inhibitor of human coenzyme Q (COQ7), interferes with ubiquinone (UQ) synthesis. COQ7-IN-1 does not disturb physiological cell growth of human normal culture cells. COQ7-IN-1 can be used for the research of the balance between UQ supplementation pathways: de novo UQ synthesis and extracellular UQ uptake .

HY-137295

Ingenol 3,20-dibenzoate	PKC Apoptosis	Inflammation/Immunology
Ingenol 3,20-dibenzoate is a potent protein kinase C (PKC) isoform-selective agonist. Ingenol 3,20-dibenzoate induces selective translocation of nPKC-delta, -epsilon, and -theta and PKC-mu from the cytosolic fraction to the particulate fraction and induces morphologically typical apoptosis through de novo synthesis of macromolecules. Ingenol 3,20-dibenzoate increases the IFN-γ production and degranulation by NK cells, especially when NK cells are stimulated by NSCLC cells .

HY-W012865

Tartronic acid	Carnitine Palmitoyltransferase (CPT) Endogenous Metabolite FABP PPAR	Metabolic Disease
Tartronic acid, a dicarboxylic acid derive, is an inhibitor of the transformation of carbohydrates into fat under fat-deficient diet conditions. Tartronic acid promotes 3T3-L1 adipocyte differentiation by increasing the protein expression of FABP-4, PPARγ and SREBP-1. Tartronic acid promotes de novo lipogenesis and inhibits CPT-1β by upregulating acetyl-CoA and malonyl-CoA. Tartronic acid promotes weight gain and induces adipocyte hypertrophy in epididymal white adipose tissue and lipid accumulation in the livers of high-fat diet induced obese mice. Tartronic acid can be used for lipid metabolic disease research .

HY-14521B

Lometrexol hydrate 3 Publications Verification DDATHF hydrate	Antifolate Apoptosis Caspase Bcl-2 Family	Cancer
Lometrexol (DDATHF) hydrate, an antipurine antifolate, can inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT) but do not induce detectable levels of DNA strand breaks. Lometrexol hydrate can further inhibit de novo purine synthesis, causing abnormal cell proliferation and apoptosis, even cell cycle arrest. Lometrexol hydrate has anticancer activity. Lometrexol hydrate also is a potent human Serine hydroxymethyltransferase1/2 (hSHMT1/2) inhibitor .

HY-N10706A

3-Keto sphinganine (d18:0) hydrochloride	Endogenous Metabolite	Cardiovascular Disease
3-Keto sphinganine (d18:0) hydrochloride serves as the substrate for 3-keto-dihydrosphingosine reductase in the de novo sphingolipid synthesis pathway, and is a key intermediate in the de novo synthesis of sphingoid long-chain bases. 3-Keto sphinganine (d18:0) hydrochloride can be used in studies related to thrombocytopenia, anemia .

HY-134433A

GDP-L-fucose disodium	Endogenous Metabolite	Metabolic Disease
GDP-L-fucose disodium is a nucleotide sugar that is a key substrate for the biosynthesis of fucose oligosaccharides. GDP-L-fucose disodium provides the fucose moiety for the oligosaccharides. The formation of GDP-L-fucose disodium occurs through two pathways, the major de novo metabolic pathway and the minor remedial metabolic pathway .

HY-13247

Setrobuvir ANA598	DNA/RNA Synthesis HCV SARS-CoV	Infection
Setrobuvir (ANA598) is an orally active non-nucleosidic HCV NS5B polymerase inhibitor. ANA-598 inhibits both de novo RNA synthesis and primer extension, with IC₅₀s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS-CoV-2 RdRp and induces RdRp inhibition .

HY-14521A

Lometrexol disodium 3 Publications Verification DDATHF disodium	Antifolate Apoptosis Caspase Bcl-2 Family	Cancer
Lometrexol (DDATHF) disodium, an antipurine antifolate, can inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT) but do not induce detectable levels of DNA strand breaks. Lometrexol disodium can further inhibit de novo purine synthesis, causing abnormal cell proliferation and apoptosis, even cell cycle arrest. Lometrexol disodium has anticancer activity. Lometrexol disodium also is a potent human Serine hydroxymethyltransferase1/2 (hSHMT1/2) inhibitor .

HY-125818S3

Cytidine-5'-triphosphate-13C9 dilithium Cytidine triphosphate-13C9 dilithium; 5'-CTP-13C9 dilithium	Isotope-Labeled Compounds DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Endogenous Metabolite	Metabolic Disease
Cytidine-5'-triphosphate- ¹³C₉ (Cytidine triphosphate- ¹³C₉ dilithium; 5'-CTP- ¹³C₉) dilithium is ¹³C-labeled Cytidine-5'-triphosphate (HY-125818). Cytidine 5′-triphosphate (Cytidine triphosphate; 5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule in the de novo pyrimidine biosynthetic pathway in T. gondii.

HY-142080

Pimeloyl-CoA Pimeloyl-coenzyme A	Endogenous Metabolite	Metabolic Disease
Pimeloyl-CoA is a key precursor compound in the biotin synthesis pathway, which can promote the de novo synthesis of biotin. Pimeloyl-CoA is mainly used in the study of microbial metabolic mechanisms, especially the analysis of biotin synthesis pathways and basic research on the biosynthesis of related antibiotics or vitamins .

HY-N6723S

Fumonisin B2-13C34	Isotope-Labeled Compounds	Infection
Fumonisin B2- ¹³C₃₄ is the ¹³C labeled Fumonisin B2 (HY-N6723) . Fumonisin B2, a mycotoxin produced by Fusarium moniliforme in various grains, is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis .

HY-126585S

SAICAR-d3	Endogenous Metabolite	Metabolic Disease
SAICAR-d₃ is the deuterium labeled SAICAR. SAICAR is an intermediate of de novo purine nucleotide biosynthesis, activates pyruvate kinase isoform M2 (PKM2) in an isozyme-selective manner, with an EC₅₀ of 0.3 mM. SAICAR stimulates PKM2 and promotes cancer cell survival in glucose-limited conditions .

Cat. No.	Product Name

HY-L0087V

Life Chemicals HTS Compound Collection	503,810 compounds
Life Chemicals Collection of small organic molecules for high-throughput screening currently contains 503,810 off-the-shelf products. The Collection is being permanently replenished with de novo designed products having optimal physicochemical parameters for drug discovery.

HY-L182

Fatty Acids Compound Library

285 compounds

Fatty acids (FAs) are the main components of lipids. The synthesis of fatty acids mainly involves the Triglyceride (TG) cycle and De Novo Lipogenesis (DNL). Fatty acids which exist widely in organisms are components of cell membranes and play an indispensable role in cell signaling. In addition, FFAs can be taken up from circulating plasma by all mitochondria-containing cells, and they are metabolized by β-oxidation and the citric acid cycle to release large amounts of energy in the form of ATP. Abnormal fatty acid metabolism is associated with the occurrence and development of cardiovascular diseases, diabetes, fatty liver, hyperthyroidism, and other diseases.

MCE offers a unique collection of fatty acid compounds. Fatty Acids Compound Library is an important tool for the study of energy metabolism and drug development of metabolism-related diseases.

Cat. No.	Product Name	Type

HY-13689G

Go 6983

Fluorescent Dyes

Go 6983 GMP is Go 6983 (HY-13689) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Go 6983 is a dual inhibitor targeting Suv39h1/2 (KMT1A/KMT1B) and PKC, as well as a transcriptional activator capable of inducing DNA hypomethylation. Go 6983 stimulates the transcription of Prdm14 by reducing Suv39h1/2 protein levels, decreasing histone modifications in the Prdm14 promoter region, and increasing the recruitment of RNA polymerase II. Go 6983 induces genome-wide DNA hypomethylation by inhibiting de novo methyltransferase expression and increasing Tet1/Tet2 levels, thereby promoting self-renewal and pluripotency maintenance of stem cells. Meanwhile, Go 6983 can block PKC-mediated signaling pathways to reduce the expression of EMT-related genes and eliminate the upregulation of antioxidant genes downstream of NRF2. Go 6983 is mainly used in mechanism studies related to myocardial ischemia/reperfusion injury .

Cat. No.	Product Name	Type

HY-158712

3'-ONH2-dATP sodium solution (100 mM)

Biochemical Assay Reagents

3'-ONH2-dATP (sodium) solution (100 mM) is a 3'-O-blocked reversible terminator deoxynucleotide triphosphate.3'-ONH2-dATP (sodium) solution (100 mM) stops DNA polymerization after single-nucleotide addition to an initiator strand, and its 3'-ONH2 blocking group can be removed to restore a free 3'-OH for subsequent extension.3'-ONH2-dATP (sodium) solution (100 mM) incorporates into an oligonucleotide chain by engineered terminal deoxynucleotidyl transferase from Zonotrichia albicollis to enable template-free, stepwise de novo enzymatic DNA synthesis .

HY-N6614

L-Galactose

Biochemical Assay Reagents

L-Galactose is a key intermediate in the de novo synthesis of vitamin C (L-ascorbic acid) in plants. It is converted into L-ascorbic acid by participating in the VTC2 cycle and enzymatic steps, exerting antioxidant activities, maintaining cell structure, and participating in the carbon flow distribution of photosynthesis. L-Galactose can be used to study the analysis of the synthesis pathway of vitamin C in plant physiology .

HY-134433A

GDP-L-fucose disodium	Biochemical Assay Reagents
GDP-L-fucose disodium is a nucleotide sugar that is a key substrate for the biosynthesis of fucose oligosaccharides. GDP-L-fucose disodium provides the fucose moiety for the oligosaccharides. The formation of GDP-L-fucose disodium occurs through two pathways, the major de novo metabolic pathway and the minor remedial metabolic pathway .

HY-13689G

Go 6983

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-114118

Semaglutide Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118B

Semaglutide acetate Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118A

Semaglutide TFA Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P2048

MOTS-c (human) 1 Publications Verification	Apoptosis GLUT AMPK	Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
MOTS-c (human) is a blood-brain barrier-penetrating, mitochondrial-derived peptide that modulates the AMPK/PGC-1α pathway to enhance insulin sensitivity. MOTS-c (human) inhibits the folate cycle and de novo purine synthesis, increases AICAR levels to activate AMPK, and then regulates the Nrf2/Keap1 antioxidant pathway and inhibits the NF-κB inflammatory pathway, while promoting mitochondrial biogenesis and energy metabolism. MOTS-c (human) has the effects of improving glucose and lipid metabolism, anti-oxidative stress, anti-inflammatory and neuroprotection, and can be used in the study of type 2 diabetes, traumatic brain injury, inflammatory diseases and aging-related metabolic disorders .

HY-114118CP

Semaglutide (crude)	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide (crude) is the crude form of Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances Autophagy, inhibits oxidative stress and Apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S1

Semaglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P2048A

MOTS-c(human) acetate 1 Publications Verification	AMPK GLUT	Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
MOTS-c (human) acetate is a blood-brain barrier-penetrating, mitochondrial-derived peptide that modulates the AMPK/PGC-1α pathway to enhance insulin sensitivity. MOTS-c (human) acetate inhibits the folate cycle and de novo purine synthesis, increases AICAR levels to activate AMPK, and then regulates the Nrf2/Keap1 antioxidant pathway and inhibits the NF-κB inflammatory pathway, while promoting mitochondrial biogenesis and energy metabolism. MOTS-c (human) acetate has the effects of improving glucose and lipid metabolism, anti-oxidative stress, anti-inflammatory and neuroprotection, and can be used in the study of type 2 diabetes, traumatic brain injury, inflammatory diseases and aging-related metabolic disorders .

HY-P10329

KK14(R)	Fungal	Infection
KK14(R) is an analog of the de novo synthetic peptide KK14, which exhibits antifungal activity against Fusarium culmorum, Penicillium expansum and Aspergillus niger , with MICs of 6.25, 12.5 and 12.5 μg/mL, respecitvely. KK14(R) exhibits good heat- and pH-stability. KK14(R) exhibits cytotoxicity against cells Caco-2 and RAW264.7 .

HY-114118C

Semaglutide sodium	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide sodium is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide sodium promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide sodium also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide sodium has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide sodium can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991200

OM-7D3-B3	HCV Claudin	Infection
OM-7D3-B3 is an antibody-based antiviral agent targeting the tight junction protein CLDN1 (K_d=4 nM). By binding to the first extracellular domain of CLDN1, OM-7D3-B3 disrupts the formation of the CLDN1-CD81 co-receptor complex, thereby effectively inhibiting the entry of hepatitis C virus (HCV). OM-7D3-B3 not only prevents de novo and chronic HCV infections in humanized liver chimeric mice and uPA-SCID mice transplanted with human livers, but also exhibits favorable safety with no toxic effects observed. OM-7D3-B3 serves as a critical tool for research on HCV infection mechanisms and antiviral drug development .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6798

Myriocin 10+ Cited Publications Thermozymocidin; ISP-I	Infection Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Disease Research Fields Source Classification	HCV Antibiotic
Myriocin (Thermozymocidin), a fungal metabolite could be isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids. Myriocin suppresses replication of both the subgenomic HCV-1b replicon and the JFH-1 strain of genotype 2a infectious HCV, with an IC₅₀ of 3.5 μg/mL for inhibiting HCV infection .

HY-N2327

Oleamide 1 Publications Verification	Natural Products Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Oleamide is an endogenous fatty acid amide which can be synthesized de novo in the mammalian nervous system, and has been detected in human plasma.

HY-N6719

Fumonisin B1 5+ Cited Publications	Infection Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Antibiotics Antibacterial Disease Research Endogenous metabolite Disease Research Fields Other Antibiotics Source Classification	Acyltransferase
Fumonisin B1 is a mycotoxin produced from Fusarium moniliforme. Fumonisin B1 is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis. Fumonisin B1 is the most abundant and toxic fumonisin .

HY-B0199

Mycophenolate Mofetil Maximum Cited Publications 12 Publications Verification RS 61443; TM-MMF	Monophenols Classification of Application Fields Phenols Endogenous metabolite Disease Research Fields Source Classification Cancer	Drug Metabolite Apoptosis Endogenous Metabolite Bacterial
Mycophenolate mofetil (RS 61443) is the morpholinoethylester proagent of Mycophenolic acid. Mycophenolate mofetil inhibits de novo purine synthesis via the inhibition of inosine monophosphate dehydrogenase (IMPDH). Mycophenolate mofetil shows selective lymphocyte antiproliferative effects involve both T and B cells, preventing antibody formation .

HY-125818

Cytidine-5'-triphosphate 3 Publications Verification Cytidine triphosphate; 5'-CTP	Infection Natural Products Human Gut Microbiota Metabolites Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Endogenous Metabolite
Cytidine 5′-triphosphate (Cytidine triphosphate; 5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule in the de novo pyrimidine biosynthetic pathway in T. gondii .

HY-126585

SAICAR 4 Publications Verification	Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Endocrine diseases Nervous System Disorder Endogenous metabolite Disease Research Fields Source Classification Cancer	Endogenous Metabolite
SAICAR is an intermediate of de novo purine nucleotide biosynthesis, activates pyruvate kinase isoform M2 (PKM2) in an isozyme-selective manner, with an EC₅₀ of 0.3 mM. SAICAR stimulates PKM2 and promotes cancer cell survival in glucose-limited conditions .

HY-W012078

5-Methyl-2'-deoxycytidine 3 Publications Verification 5-Methyldeoxycytidine	Natural Products Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Source Classification	DNA Methyltransferase Endogenous Metabolite
5-Methyl-2'-deoxycytidine (5mdC) is an endogenous substrate of DNA methyltransferases (such as mammalian 5-C-MTase) and binds to DNA dependent on the formation of DNA stem-loop structures. 5-Methyl-2'-deoxycytidine guides de novo DNA methylation by acting as a methylation mark and activates the methylation of adjacent CpG sites in single-stranded DNA through cis action. 5-Methyl-2'-deoxycytidine regulates DNA methylation patterns by recruiting methyltransferases to specific chromatin regions, affecting chromatin condensation and gene expression. Its distribution in plant cells is related to cell proliferation and differentiation stages. The methylation level of 5-Methyl-2'-deoxycytidine is low in proliferating cells and high in differentiated cells .

HY-B0199A

Mycophenolate mofetil hydrochloride Maximum Cited Publications 12 Publications Verification RS 61443 hydrochloride; TM-MMF hydrochloride	Structural Classification Monophenols Classification of Application Fields Phenols Endogenous metabolite Disease Research Fields Source Classification Cancer	Interleukin Related
Mycophenolate mofetil (RS 61443; TM-MMF) hydrochloride is an orally active antimetabolic immunosuppressant with antiproliferative and anti-inflammatory properties. Mycophenolate mofetil hydrochloride significantly inhibits the production of B, T lymphocytes and the proliferation of smooth muscle cells by selectively blocking the de novo purine synthesis pathway. Mycophenolate mofetil hydrochloride effectively reduces adventitial inflammation, medial necrosis and intimal thickening in rat aortic allografts, and decreases the number of lymphocytes expressing the IL-2 receptor, thereby delaying xenograft rejection. Mycophenolate mofetil hydrochloride shows certain toxicity in a hamster-to-rat limb xenotransplantation model when used in combination with FK506 (HY-13756). Mycophenolate mofetil hydrochloride is widely used in studies related to allograft arteriosclerosis (chronic rejection) .

HY-N6723

Fumonisin B2	Infection Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Antibiotics Antibacterial Disease Research Endogenous metabolite Disease Research Fields Other Antibiotics Source Classification	Ceramidase Acyltransferase
Fumonisin B2 is a selective ceramide synthase inhibitor and carcinogenic mycotoxin with toxicity comparable to that of Fumonisin B1 (HY-N6719). Fumonisin B2 inhibits de novo sphingolipid biosynthesis by blocking the amide bond formation between fatty acids and dihydrosphingosine, which leads to a massive intracellular accumulation of free dihydrosphingosine, altered sphingosine levels, subsequent inhibition of cell proliferation, and induction of cell death. Fumonisin B2 is used to investigate the pathogenesis of diseases associated with Fusarium verticillioides contamination, including equine leukoencephalomalacia, porcine pulmonary edema syndrome, human esophageal cancer, and rat hepatocellular carcinoma .

HY-N8060A

Orotidine 5′-monophosphate trisodium 1 Publications Verification Orotidine monophosphate trisodium; Orotidylic acid trisodium	Alkaloids Classification of Application Fields Other Alkaloids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite DNA/RNA Synthesis
Orotidine 5'-monophosphate trisodium is a pyrimidine nucleotide. Orotidine 5'-monophosphate trisodium is synthesized via the de novo synthesis pathway for DNA synthesis in a large number of microorganisms including M. tuberculosis, S. cerevisiae, S. typhimurium and P. falciparum to name a few. The synthesis of orotidine 5'-monophosphate trisodium uses phosphoribosyl pyrophosphate (PRPP) and orotic acid (OA) as the substrates catalyzed by orotate phosphoribosyltransferase (OPRT) .

HY-133154

Carboxyaminoimidazole ribotide 2 Publications Verification CAIR; 4-Carboxy-AIR	Infection Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Carboxyaminoimidazole ribotide (CAIR) is a metabolite of E. coli. Carboxyaminoimidazole ribotide can be used to detect distinctive features of E. coli PurE active site and synthesis fungal de novo purine .

HY-133157

FAICAR 5-Formamidoimidazole-4-carboxamide ribotide	Source Classification	DNA/RNA Synthesis
FAICAR (5-Formamidoimidazole-4-carboxamide ribotide) is a purine nucleotide and the IMP cyclohydrolase substrate of Cryptococcus neoformans ATIC. It is a key intermediate in the de novo purine synthesis pathway. FAICAR can be used in studies related to Cryptococcus neoformans infection .

HY-137295

Ingenol 3,20-dibenzoate	Classification of Application Fields Terpenoids Diterpenoids Euphorbia esula L. Euphorbiaceae Plants Inflammation/Immunology Disease Research Fields Source Classification	PKC Apoptosis
Ingenol 3,20-dibenzoate is a potent protein kinase C (PKC) isoform-selective agonist. Ingenol 3,20-dibenzoate induces selective translocation of nPKC-delta, -epsilon, and -theta and PKC-mu from the cytosolic fraction to the particulate fraction and induces morphologically typical apoptosis through de novo synthesis of macromolecules. Ingenol 3,20-dibenzoate increases the IFN-γ production and degranulation by NK cells, especially when NK cells are stimulated by NSCLC cells .

HY-134433A

GDP-L-fucose disodium	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
GDP-L-fucose disodium is a nucleotide sugar that is a key substrate for the biosynthesis of fucose oligosaccharides. GDP-L-fucose disodium provides the fucose moiety for the oligosaccharides. The formation of GDP-L-fucose disodium occurs through two pathways, the major de novo metabolic pathway and the minor remedial metabolic pathway .

HY-B0199R

Mycophenolate Mofetil (Standard) RS 61443 (Standard); TM-MMF (Standard)	Structural Classification Monophenols Phenols Endogenous metabolite Source Classification	Reference Standards Interleukin Related
Mycophenolate Mofetil (Standard) is the analytical standard of Mycophenolate Mofetil. This product is intended for research and analytical applications. Mycophenolate mofetil (RS 61443; TM-MMF) hydrochloride is an orally active antimetabolic immunosuppressant with antiproliferative and anti-inflammatory properties. Mycophenolate mofetil hydrochloride significantly inhibits the production of B, T lymphocytes and the proliferation of smooth muscle cells by selectively blocking the de novo purine synthesis pathway. Mycophenolate mofetil hydrochloride effectively reduces adventitial inflammation, medial necrosis and intimal thickening in rat aortic allografts, and decreases the number of lymphocytes expressing the IL-2 receptor, thereby delaying xenograft rejection. Mycophenolate mofetil hydrochloride shows certain toxicity in a hamster-to-rat limb xenotransplantation model when used in combination with FK506 (HY-13756). Mycophenolate mofetil hydrochloride is widely used in studies related to allograft arteriosclerosis (chronic rejection) .

HY-142080

Pimeloyl-CoA Pimeloyl-coenzyme A	Human Gut Microbiota Metabolites Endogenous metabolite Source Classification	Endogenous Metabolite
Pimeloyl-CoA is a key precursor compound in the biotin synthesis pathway, which can promote the de novo synthesis of biotin. Pimeloyl-CoA is mainly used in the study of microbial metabolic mechanisms, especially the analysis of biotin synthesis pathways and basic research on the biosynthesis of related antibiotics or vitamins .

HY-W012078R

5-Methyl-2'-deoxycytidine (Standard) 1 Publications Verification 5-Methyldeoxycytidine (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards DNA Methyltransferase Endogenous Metabolite
5-Methyl-2'-deoxycytidine (5mdC) is an endogenous substrate of DNA methyltransferases (such as mammalian 5-C-MTase) and binds to DNA dependent on the formation of DNA stem-loop structures. 5-Methyl-2'-deoxycytidine guides de novo DNA methylation by acting as a methylation mark and activates the methylation of adjacent CpG sites in single-stranded DNA through cis action. 5-Methyl-2'-deoxycytidine regulates DNA methylation patterns by recruiting methyltransferases to specific chromatin regions, affecting chromatin condensation and gene expression. Its distribution in plant cells is related to cell proliferation and differentiation stages. The methylation level of 5-Methyl-2'-deoxycytidine is low in proliferating cells and high in differentiated cells .

HY-117224

Rhizopterin Formylpteroic acid	Microorganisms Ketones, Aldehydes, Acids Source Classification	Bacterial Endogenous Metabolite
Rhizopterin is a growth factor that can form rhizobactin de novo in synthetic medium lacking folate .

HY-N2327R

Oleamide (Standard)	Structural Classification Natural Products Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Reference Standards Endogenous Metabolite
Oleamide (Standard) is the analytical standard of Oleamide. This product is intended for research and analytical applications. Oleamide is an endogenous fatty acid amide which can be synthesized de novo in the mammalian nervous system, and has been detected in human plasma.

HY-157528

CJ28	Structural Classification Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Endogenous Metabolite
CJ28 is a cortisol biosynthesis inhibitor that significantly inhibits basal and stimulated cortisol production in human adrenal carcinoma cell lines. CJ28 exhibits inhibitory effects by reducing steroidogenesis and de novo cholesterol biosynthesis .

HY-N6798R

Myriocin (Standard) Thermozymocidin (Standard); ISP-I (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source Classification	Reference Standards HCV Antibiotic
Myriocin (Standard) is the analytical standard of Myriocin. This product is intended for research and analytical applications. Myriocin (Thermozymocidin), a fungal metabolite could be isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids. Myriocin suppresses replication of both the subgenomic HCV-1b replicon and the JFH-1 strain of genotype 2a infectious HCV, with an IC50 of 3.5 μg/mL for inhibiting HCV infection[1][2][3].

HY-N10706

3-Keto sphinganine (d18:0)	Structural Classification Natural Products Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Endogenous Metabolite
3-Keto sphinganine (d18:0) serves as the substrate for 3-keto-dihydrosphingosine reductase in the de novo sphingolipid synthesis pathway, and is a key intermediate in the de novo synthesis of sphingoid long-chain bases. 3-Keto sphinganine (d18:0) can be used in studies related to thrombocytopenia, anemia .

HY-N18066

Esculeogenin A	Structural Classification Solanum lycopersicum L. Solanaceae Plants Steroids Source Classification	Drug Derivative Acyltransferase NF-κB PPAR Fatty Acid Synthase (FASN) Keap1-Nrf2
Esculeogenin A is the sapogenol of tomato saponin Esculeoside A (HY-N18067). Esculeogenin A is an orally active hepatoprotective, hypolipidemic, and antioxidant agent. Esculeogenin A regulates molecular targets like PPARα, SREBP1, Nrf2, NF-κB, ACAT1/ACAT2 to promote hepatic fatty acid oxidation, suppress de novo lipogenesis, enhance antioxidant defense, and inhibit inflammation. Esculeogenin A improves liver function, alleviates hyperlipidemia, and inhibits hepatic steatosis and foam cell formation, preventing nonalcoholic fatty liver disease in high-fat-diet-fed rats and reducing atherosclerotic lesions in apoE-deficient mice. Esculeogenin A can be used for the research of nonalcoholic fatty liver disease, atherosclerosis, and hyperlipidemia .

Cat. No.	Product Name	Chemical Structure

HY-114118S3

Semaglutide-13C6,15N TFA

Semaglutide- ¹³C₆, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-19939S

VX-984 4 Publications Verification
VX-984 is an orally active, potent, selective and BBB-penetrated DNA-PK inhibitor. VX-984 efficiently inhibits NHEJ (non-homologous end joining) and increases DSBs (DNA double-strand breaks). VX-984 can be used for glioblastomas (GBM) and non-small cell lung cancer (NSCLC) research. VX-984 is a de novo deuterium .

HY-131968

BMS-986202

1 Publications Verification

BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

HY-114118S1

Semaglutide-d8 tetraTFA

Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8

Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-B0199S

Mycophenolate Mofetil-d4

Mycophenolate Mofetil-d₄ is the deuterium labeled Mycophenolate Mofetil. Mycophenolate mofetil (RS 61443; TM-MMF) hydrochloride is an orally active antimetabolic immunosuppressant with antiproliferative and anti-inflammatory properties. Mycophenolate mofetil hydrochloride significantly inhibits the production of B, T lymphocytes and the proliferation of smooth muscle cells by selectively blocking the de novo purine synthesis pathway. Mycophenolate mofetil hydrochloride effectively reduces adventitial inflammation, medial necrosis and intimal thickening in rat aortic allografts, and decreases the number of lymphocytes expressing the IL-2 receptor, thereby delaying xenograft rejection. Mycophenolate mofetil hydrochloride shows certain toxicity in a hamster-to-rat limb xenotransplantation model when used in combination with FK506 (HY-13756). Mycophenolate mofetil hydrochloride is widely used in studies related to allograft arteriosclerosis (chronic rejection) .

HY-W740027

5-Methyl-2'-deoxycytidine-d3

5-Methyl-2'-deoxycytidine-d₃ (5-Methyldeoxycytidine-d₃) is the deuterium labeled Methyl-2'-deoxycytidine (HY-W012078). 5-Methyl-2'-deoxycytidine (5mdC) is an endogenous substrate of DNA methyltransferases (such as mammalian 5-C-MTase) and binds to DNA dependent on the formation of DNA stem-loop structures. 5-Methyl-2'-deoxycytidine guides de novo DNA methylation by acting as a methylation mark and activates the methylation of adjacent CpG sites in single-stranded DNA through cis action. 5-Methyl-2'-deoxycytidine regulates DNA methylation patterns by recruiting methyltransferases to specific chromatin regions, affecting chromatin condensation and gene expression. Its distribution in plant cells is related to cell proliferation and differentiation stages. The methylation level of 5-Methyl-2'-deoxycytidine is low in proliferating cells and high in differentiated cells .

HY-125818S3

Cytidine-5'-triphosphate-13C9 dilithium

Cytidine-5'-triphosphate- ¹³C₉ (Cytidine triphosphate- ¹³C₉ dilithium; 5'-CTP- ¹³C₉) dilithium is ¹³C-labeled Cytidine-5'-triphosphate (HY-125818). Cytidine 5′-triphosphate (Cytidine triphosphate; 5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule in the de novo pyrimidine biosynthetic pathway in T. gondii.

HY-N6723S

Fumonisin B2-13C34
Fumonisin B2- ¹³C₃₄ is the ¹³C labeled Fumonisin B2 (HY-N6723) . Fumonisin B2, a mycotoxin produced by Fusarium moniliforme in various grains, is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis .

HY-126585S

SAICAR-d3
SAICAR-d₃ is the deuterium labeled SAICAR. SAICAR is an intermediate of de novo purine nucleotide biosynthesis, activates pyruvate kinase isoform M2 (PKM2) in an isozyme-selective manner, with an EC₅₀ of 0.3 mM. SAICAR stimulates PKM2 and promotes cancer cell survival in glucose-limited conditions .

HY-N6719S

Fumonisin B1-13C34
Fumonisin B1- ¹³C₃₄ is the ¹³C labeled Fumonisin B1 (HY-N6719) . Fumonisin B1 is a mycotoxin produced from Fusarium moniliforme. Fumonisin B1 is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis. Fumonisin B1 is the most abundant and toxic fumonisin .

HY-B0199AS

Mycophenolate Mofetil-d4 hydrochloride

Mycophenolate Mofetil-d₄ hydrochloride is deuterated labeled Mycophenolate mofetil hydrochloride (HY-B0199A). Mycophenolate mofetil (RS 61443; TM-MMF) hydrochloride is an orally active antimetabolic immunosuppressant with antiproliferative and anti-inflammatory properties. Mycophenolate mofetil hydrochloride significantly inhibits the production of B, T lymphocytes and the proliferation of smooth muscle cells by selectively blocking the de novo purine synthesis pathway. Mycophenolate mofetil hydrochloride effectively reduces adventitial inflammation, medial necrosis and intimal thickening in rat aortic allografts, and decreases the number of lymphocytes expressing the IL-2 receptor, thereby delaying xenograft rejection. Mycophenolate mofetil hydrochloride shows certain toxicity in a hamster-to-rat limb xenotransplantation model when used in combination with FK506 (HY-13756). Mycophenolate mofetil hydrochloride is widely used in studies related to allograft arteriosclerosis (chronic rejection) .

HY-10250S1

Triciribine phosphate-d3

Triciribine phosphate-d3 (TCN-P-d3) is a deuterated compound of Triciribine phosphate (TCN-P). TCN-P inhibits adenosine monophosphate (AMP)-activated protein kinase through an allosteric mechanism, affecting the first key step in de novo purine biosynthesis. Triciribine phosphate also inhibits inosine monophosphate dehydrogenase, which is the first key step in guanosine nucleotide synthesis. Triciribine phosphate does not affect ligase activity .

HY-125818S1

Cytidine-5′-triphosphate-d14 disodium

Cytidine-5′-triphosphate-d₁₄ disodium is the deuterium labeled Cytidine-5'-triphosphate . Cytidine 5′-triphosphate (Cytidine triphosphate;5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule in the de novo pyrimidine biosynthetic pathway in T. gondii .

HY-W754064

Cytidine-5'-triphosphate-13C5

Cytidine-5'-triphosphate- ¹³C₅ (Cytidine triphosphate- ¹³C₅) is the ¹³C-labeled Cytidine-5'-triphosphate (HY-125818). Cytidine 5′-triphosphate (Cytidine triphosphate; 5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule?in the de novo?pyrimidine biosynthetic pathway in?T. gondii .

HY-125818S4

Cytidine-5'-triphosphate-d14 dilithium

Cytidine-5'-triphosphate-d₁₄ (Cytidine triphosphate-d₁₄ dilithium; 5'-CTP-d₁₄) dilithium is deuterium labeled Cytidine-5'-triphosphate (HY-125818). Cytidine 5′-triphosphate (Cytidine triphosphate; 5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule in the de novo pyrimidine biosynthetic pathway in T. gondii.

HY-125818S6

Cytidine-5'-triphosphate-15N3 dilithium

Cytidine-5'-triphosphate- ¹⁵N₃ (Cytidine triphosphate- ¹⁵N₃ dilithium; 5'-CTP- ¹⁵N₃) dilithium is ¹⁵N labeled Cytidine-5'-triphosphate (HY-125818). Cytidine 5′-triphosphate (Cytidine triphosphate; 5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule in the de novo pyrimidine biosynthetic pathway in T. gondii.

HY-125818S2

Cytidine-5'-triphosphate-13C,d1 dilithium

Cytidine-5'-triphosphate- ¹³C,d₁ (Cytidine triphosphate- ¹³C,d₁ dilithium; 5'-CTP- ¹³C,d₁) dilithium is deuterium and ¹³C-labeled Cytidine-5'-triphosphate (HY-125818). Cytidine 5′-triphosphate (Cytidine triphosphate; 5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule in the de novo pyrimidine biosynthetic pathway in T. gondii.

HY-125818S5

Cytidine-5'-triphosphate-15N3,d14 dilithium

Cytidine-5'-triphosphate- ¹⁵N₃,d₁₄ (Cytidine triphosphate- ¹⁵N₃,d₁₄ dilithium; 5'-CTP- ¹⁵N₃,d₁₄) dilithium is deuterium and ¹⁵N labeled Cytidine-5'-triphosphate (HY-125818). Cytidine 5′-triphosphate (Cytidine triphosphate; 5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule in the de novo pyrimidine biosynthetic pathway in T. gondii.

HY-166594S

Deucravacitinib-13C,d3

Deucravacitinib- ¹³C,d₃ is the ¹³C- and deuterium labeled Deucravacitinib. Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC₅₀=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis .

Cat. No.	Product Name		Classification

HY-125818

Cytidine-5'-triphosphate 3 Publications Verification Cytidine triphosphate; 5'-CTP		Nucleotide Analogs
Cytidine 5′-triphosphate (Cytidine triphosphate; 5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule in the de novo pyrimidine biosynthetic pathway in T. gondii .

HY-18762

6-Thio-2'-Deoxyguanosine 2 Publications Verification 6-thio-dG; β-TGdR		Nucleoside Analogs Guanosine
6-Thio-2'-Deoxyguanosine is a nucleoside analogue that can be incorporated into de novo-synthesized telomeres by telomerase.

HY-W013100

Cytidine-5'-triphosphate disodium 3 Publications Verification Cytidine triphosphate disodium; 5'-CTP disodium		Nucleotide Analogs Cytidine Nucleotide
Cytidine-5'-triphosphate (Cytidine triphosphate; 5'-CTP) disodium is a nucleoside triphosphate, that is invovled in biosynthesis of DNA, RNA and lipid. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate disodium is an essential biomolecule in the de novo pyrimidine biosynthetic pathway in T. gondii .

HY-125818C

Cytidine-5'-triphosphate disodium hydrate Cytidine triphosphate disodium hydrate; 5'-CTP disodium hydrate		Nucleotide Analogs Cytidine Nucleotide
Cytidine 5′-triphosphate is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule in the de novo pyrimidine biosynthetic pathway in T. gondii .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13689G

Go 6983	PKC Histone Methyltransferase DNA Methyltransferase DNA/RNA Synthesis	Inflammation/Immunology
Go 6983 GMP is Go 6983 (HY-13689) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Go 6983 is a dual inhibitor targeting Suv39h1/2 (KMT1A/KMT1B) and PKC, as well as a transcriptional activator capable of inducing DNA hypomethylation. Go 6983 stimulates the transcription of Prdm14 by reducing Suv39h1/2 protein levels, decreasing histone modifications in the Prdm14 promoter region, and increasing the recruitment of RNA polymerase II. Go 6983 induces genome-wide DNA hypomethylation by inhibiting de novo methyltransferase expression and increasing Tet1/Tet2 levels, thereby promoting self-renewal and pluripotency maintenance of stem cells. Meanwhile, Go 6983 can block PKC-mediated signaling pathways to reduce the expression of EMT-related genes and eliminate the upregulation of antioxidant genes downstream of NRF2. Go 6983 is mainly used in mechanism studies related to myocardial ischemia/reperfusion injury .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

novo

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

GMP Molecules

Natural
Products